

# Malaria vaccines indicator

---

## Market (feasibility)

### **Available vaccines, licensing status, prequalification status, presentation, formulation, dosage and route of administration**

Two malaria vaccines are recommended by WHO for programmatic use in children living in *P. falciparum* malaria-endemic areas: RTS,S/AS01 (Mosquirix) and R21/Matrix-M. [1](#) Both vaccines have WHO prequalification. [2](#), [3](#), [4](#)

Detailed information on the available products can be found in the vaccine comparison table, including licensing, presentation, formulation, dosage and route of administration. [5](#)

The malaria vaccination series for each child should be completed with the same product whenever feasible. However, if the product used for a prior dose is unavailable or unknown, the series should be completed with either of the available WHO-recommended malaria vaccines. Restarting the vaccine series is not recommended. [1](#)

---

## Sources

1.

World Health Organization (2024). Malaria vaccines: WHO position paper, May 2024. Wkly Epidemiol Rec. 99(19):225–248 (<https://www.who.int/publications/i/item/who-wer-9919-225-248>, accessed 13 May 2026).

2.

World Health Organization (2026). RTS,S/AS01 (Mosquirix) (<https://extranet.who.int/prequal/vaccines/p/mosquirix> , accessed 13 May 2026).

3.

World Health Organization (2026). R21/Matrix-M liquid one-dose vial (<https://extranet.who.int/prequal/vaccines/p/r21-malaria>, accessed 13 May 2026).

4.

World Health Organization (2026). R21/Matrix-M liquid two-dose vial (<https://extranet.who.int/prequal/vaccines/p/cyvacc>, accessed 13 May 2026).

5.

For specific product characteristics see [the comparison table](#)